Multivariate analysis of prognostic impact of cyclin B1 and FLIPI parameters on overall survival
. | Adverse factor . | Relative risk . | Range . | P . |
|---|---|---|---|---|
| Age | ≥ 60 | 5.6 | 1.7-18.7 | .005 |
| Ann Arbor stage | III-IV | 4.4 | 1.3-15.2 | .020 |
| Nodal sites | > 4 | 0.3 | 0.09-1.02 | .054 |
| Hemoglobin | < 12 g/dL | 3.0 | 1.0-8.9 | .043 |
| Serum LDH level | > ULN | 1.0 | 0.33-3 | .99 |
| Cyclin B1* | ≤ 59 | 3.0 | 1.1-8.3 | .036 |
. | Adverse factor . | Relative risk . | Range . | P . |
|---|---|---|---|---|
| Age | ≥ 60 | 5.6 | 1.7-18.7 | .005 |
| Ann Arbor stage | III-IV | 4.4 | 1.3-15.2 | .020 |
| Nodal sites | > 4 | 0.3 | 0.09-1.02 | .054 |
| Hemoglobin | < 12 g/dL | 3.0 | 1.0-8.9 | .043 |
| Serum LDH level | > ULN | 1.0 | 0.33-3 | .99 |
| Cyclin B1* | ≤ 59 | 3.0 | 1.1-8.3 | .036 |
ULN indicates upper limit of normal.
Relative expression of RNA of probe set 34736_at